Mechanism of Action

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to stimulate growth hormone (GH) release from the pituitary gland. However, the specific molecular mechanisms by which CJC-1295 operates are not detailed in the available evidence.

The provided research papers discuss CJC-1295 within the broader context of performance-enhancing peptides that modulate the GH-IGF1 axis, but they do not provide explicit mechanistic details about how CJC-1295 functions at the molecular or physiological level. The studies focus primarily on clinical applications, safety considerations, and regulatory aspects of peptide therapies rather than their underlying biochemical mechanisms.

One clinical trial (NCT00267527) investigated CJC-1295 in HIV patients with visceral obesity, but this study was terminated and does not provide mechanistic insights from its results.

Evidence Limitation: The current evidence base lacks detailed molecular and physiological mechanism data for CJC-1295. While it is classified among peptides affecting the GH-IGF1 axis, the specific pathways, receptor interactions, and downstream effects require additional research to be fully characterized.

Disclaimer: This information is for educational purposes only and should not be considered medical advice. Consult with a healthcare professional for any medical decisions.